CL2015002720A1 - Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc. - Google Patents

Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.

Info

Publication number
CL2015002720A1
CL2015002720A1 CL2015002720A CL2015002720A CL2015002720A1 CL 2015002720 A1 CL2015002720 A1 CL 2015002720A1 CL 2015002720 A CL2015002720 A CL 2015002720A CL 2015002720 A CL2015002720 A CL 2015002720A CL 2015002720 A1 CL2015002720 A1 CL 2015002720A1
Authority
CL
Chile
Prior art keywords
composition
factor viii
chimeric polypeptide
fviii
pharmaceutical kit
Prior art date
Application number
CL2015002720A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CL2015002720A1 publication Critical patent/CL2015002720A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2015002720A 2013-03-15 2015-09-15 Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc. CL2015002720A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
CL2015002720A1 true CL2015002720A1 (es) 2016-11-04

Family

ID=50771579

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002720A CL2015002720A1 (es) 2013-03-15 2015-09-15 Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.

Country Status (20)

Country Link
US (3) US9623088B2 (enExample)
EP (3) EP4122487A1 (enExample)
JP (5) JP6330026B2 (enExample)
AU (4) AU2014228506A1 (enExample)
CA (1) CA2899737A1 (enExample)
CL (1) CL2015002720A1 (enExample)
DK (1) DK2968477T3 (enExample)
EA (2) EA201890671A1 (enExample)
ES (2) ES2926798T3 (enExample)
HU (1) HUE047933T2 (enExample)
LT (1) LT2968477T (enExample)
PH (2) PH12015501801B1 (enExample)
PL (2) PL3666283T3 (enExample)
PT (2) PT3666283T (enExample)
RS (1) RS60003B1 (enExample)
SG (2) SG11201505924TA (enExample)
SI (1) SI2968477T1 (enExample)
TW (2) TWI629993B (enExample)
UY (1) UY35462A (enExample)
WO (1) WO2014144795A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069164A2 (en) * 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
CA3082043A1 (en) * 2017-11-07 2019-05-16 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
EP3870206A4 (en) * 2018-10-23 2023-04-26 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION
JP7501875B2 (ja) * 2019-02-28 2024-06-18 公立大学法人横浜市立大学 血液凝固および／または補体異常疾患の治療用組成物
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
BR112021025426A2 (pt) * 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
WO2023219379A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
WO2023219378A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
JP2525022B2 (ja) 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
CA2634663C (en) * 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
KR20150138427A (ko) 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
US20120093840A1 (en) 2009-04-06 2012-04-19 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
WO2011069164A2 (en) * 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
AU2012282875B2 (en) * 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
CA2850579A1 (en) * 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
CN104519912A (zh) * 2012-08-13 2015-04-15 诺和诺德A/S（股份有限公司） 液体因子viii制剂
EP3446700A1 (en) * 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII

Also Published As

Publication number Publication date
EA201890671A1 (ru) 2019-01-31
DK2968477T3 (da) 2020-03-09
PH12015501801B1 (en) 2019-11-20
EP3666283A1 (en) 2020-06-17
EP3666283B1 (en) 2022-06-08
JP2020186268A (ja) 2020-11-19
US20170281734A1 (en) 2017-10-05
HUE047933T2 (hu) 2020-05-28
SI2968477T1 (sl) 2020-04-30
PH12019502452A1 (en) 2021-02-08
WO2014144795A1 (en) 2014-09-18
JP2023060146A (ja) 2023-04-27
JP2021181491A (ja) 2021-11-25
TW201501722A (zh) 2015-01-16
AU2025204069A1 (en) 2025-06-26
PL2968477T3 (pl) 2020-06-15
US20210069300A1 (en) 2021-03-11
JP6934994B2 (ja) 2021-09-15
JP7240457B2 (ja) 2023-03-15
CA2899737A1 (en) 2014-09-18
UY35462A (es) 2014-10-31
LT2968477T (lt) 2020-03-10
EA201591439A1 (ru) 2016-03-31
SG11201505924TA (en) 2015-09-29
PT2968477T (pt) 2020-03-11
PL3666283T3 (pl) 2022-10-03
AU2021277601A1 (en) 2021-12-23
EP4122487A1 (en) 2023-01-25
TWI629993B (zh) 2018-07-21
RS60003B1 (sr) 2020-04-30
HK1220617A1 (en) 2017-05-12
SG10201805207QA (en) 2018-07-30
AU2025204069A9 (en) 2026-03-19
TW201842930A (zh) 2018-12-16
EA030357B1 (ru) 2018-07-31
EP2968477B1 (en) 2019-12-04
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
US12403183B2 (en) 2025-09-02
PH12015501801A1 (en) 2015-11-09
US9623088B2 (en) 2017-04-18
ES2776195T3 (es) 2020-07-29
EP2968477A1 (en) 2016-01-20
US20140308280A1 (en) 2014-10-16
PT3666283T (pt) 2022-09-13
US10786554B2 (en) 2020-09-29
ES2926798T3 (es) 2022-10-28
JP7700164B2 (ja) 2025-06-30
JP2018123161A (ja) 2018-08-09
JP6330026B2 (ja) 2018-05-23
TWI690325B (zh) 2020-04-11
AU2021277601B2 (en) 2025-03-06
AU2014228506A1 (en) 2015-08-13
JP2016516722A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
AR099079A1 (es) Variantes de región fc con propiedades de unión de fcrn modificadas
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CY1121953T1 (el) Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων
UY40420A (es) Formulación que comprende una superóxido dismutasa
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
EP3704219C0 (en) POLYPEPTIDES AND COMPOSITIONS COMPRISING SUCH POLYPEPTIDES
TW201613958A (en) MIC-1 fusion proteins and uses thereof
CY1124911T1 (el) Συνθεσεις πεπτιδιων και μεθοδοι χρησης
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
MX381286B (es) Adenovirus que comprende una fracción de unión a albúmina.
MX2016008782A (es) Variantes de region fc con union mejorada de la proteina a.
CR20160049A (es) Bioconjugados de polipéptidos de apelina sintética
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
EP3621621C0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MELOXICAM
BR112017021706A2 (pt) recipientes flexíveis com visibilidade de dispensação do produto
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
AR100888A1 (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
MX2017007458A (es) Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
IL280678A (en) Cell-penetrating peptides
EA201890671A1 (ru) Препараты полипептида фактора viii